Cargando…

Modeling human hypertrophic scars with 3D preformed cellular aggregates bioprinting

The therapeutic interventions of human hypertrophic scars (HHS) remain puzzle largely due to the lack of accepted models. Current HHS models are limited by their inability to mimic native scar architecture and associated pathological microenvironments. Here, we create a 3D functional HHS model by pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bin, Yao, Dongzhen, Zhu, Xiaoli, Cui, jirigala, Enhe, Wei, Song, Zhao, Li, Tian, Hu, Ping, Zhu, Jianjun, Li, Yuzhen, Wang, Yijie, Zhang, Xiaobing, Fu, Sha, Huang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636708/
https://www.ncbi.nlm.nih.gov/pubmed/34901543
http://dx.doi.org/10.1016/j.bioactmat.2021.09.004
_version_ 1784608584251736064
author Bin, Yao
Dongzhen, Zhu
Xiaoli, Cui
jirigala, Enhe
Wei, Song
Zhao, Li
Tian, Hu
Ping, Zhu
Jianjun, Li
Yuzhen, Wang
Yijie, Zhang
Xiaobing, Fu
Sha, Huang
author_facet Bin, Yao
Dongzhen, Zhu
Xiaoli, Cui
jirigala, Enhe
Wei, Song
Zhao, Li
Tian, Hu
Ping, Zhu
Jianjun, Li
Yuzhen, Wang
Yijie, Zhang
Xiaobing, Fu
Sha, Huang
author_sort Bin, Yao
collection PubMed
description The therapeutic interventions of human hypertrophic scars (HHS) remain puzzle largely due to the lack of accepted models. Current HHS models are limited by their inability to mimic native scar architecture and associated pathological microenvironments. Here, we create a 3D functional HHS model by preformed cellular aggregates (PCA) bioprinting, firstly developing bioink from scar decellularized extracellular matrix (ECM) and alginate-gelatin (Alg-Gel) hydrogel with suitable physical properties to mimic the microenvironmental factors, then pre-culturing patient-derived fibroblasts in this bioink to preform the topographic cellular aggregates for sequent printing. We confirm the cell aggregates preformed in bioink displayed well defined aligned structure and formed functional scar tissue self-organization after bioprinting, hence showing the potential of creating HHS models. Notably, these HHS models exhibit characteristics of early-stage HHS in gene and protein expression, which significantly activated signaling pathway related to inflammation and cell proliferation, and recapitulate in vivo tissue dynamics of scar forming. We also use the in vitro and in vivo models to define the clinically observed effects to treatment with concurrent anti-scarring drugs, and the data show that it can be used to evaluate the potential therapeutic target for drug testing. The ideal humanized scar models we present should prove useful for studying critical mechanisms underlying HHS and to rapidly test new drug targets and develop patient-specific optimal therapeutic strategies in the future.
format Online
Article
Text
id pubmed-8636708
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-86367082021-12-09 Modeling human hypertrophic scars with 3D preformed cellular aggregates bioprinting Bin, Yao Dongzhen, Zhu Xiaoli, Cui jirigala, Enhe Wei, Song Zhao, Li Tian, Hu Ping, Zhu Jianjun, Li Yuzhen, Wang Yijie, Zhang Xiaobing, Fu Sha, Huang Bioact Mater Article The therapeutic interventions of human hypertrophic scars (HHS) remain puzzle largely due to the lack of accepted models. Current HHS models are limited by their inability to mimic native scar architecture and associated pathological microenvironments. Here, we create a 3D functional HHS model by preformed cellular aggregates (PCA) bioprinting, firstly developing bioink from scar decellularized extracellular matrix (ECM) and alginate-gelatin (Alg-Gel) hydrogel with suitable physical properties to mimic the microenvironmental factors, then pre-culturing patient-derived fibroblasts in this bioink to preform the topographic cellular aggregates for sequent printing. We confirm the cell aggregates preformed in bioink displayed well defined aligned structure and formed functional scar tissue self-organization after bioprinting, hence showing the potential of creating HHS models. Notably, these HHS models exhibit characteristics of early-stage HHS in gene and protein expression, which significantly activated signaling pathway related to inflammation and cell proliferation, and recapitulate in vivo tissue dynamics of scar forming. We also use the in vitro and in vivo models to define the clinically observed effects to treatment with concurrent anti-scarring drugs, and the data show that it can be used to evaluate the potential therapeutic target for drug testing. The ideal humanized scar models we present should prove useful for studying critical mechanisms underlying HHS and to rapidly test new drug targets and develop patient-specific optimal therapeutic strategies in the future. KeAi Publishing 2021-09-08 /pmc/articles/PMC8636708/ /pubmed/34901543 http://dx.doi.org/10.1016/j.bioactmat.2021.09.004 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Bin, Yao
Dongzhen, Zhu
Xiaoli, Cui
jirigala, Enhe
Wei, Song
Zhao, Li
Tian, Hu
Ping, Zhu
Jianjun, Li
Yuzhen, Wang
Yijie, Zhang
Xiaobing, Fu
Sha, Huang
Modeling human hypertrophic scars with 3D preformed cellular aggregates bioprinting
title Modeling human hypertrophic scars with 3D preformed cellular aggregates bioprinting
title_full Modeling human hypertrophic scars with 3D preformed cellular aggregates bioprinting
title_fullStr Modeling human hypertrophic scars with 3D preformed cellular aggregates bioprinting
title_full_unstemmed Modeling human hypertrophic scars with 3D preformed cellular aggregates bioprinting
title_short Modeling human hypertrophic scars with 3D preformed cellular aggregates bioprinting
title_sort modeling human hypertrophic scars with 3d preformed cellular aggregates bioprinting
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636708/
https://www.ncbi.nlm.nih.gov/pubmed/34901543
http://dx.doi.org/10.1016/j.bioactmat.2021.09.004
work_keys_str_mv AT binyao modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT dongzhenzhu modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT xiaolicui modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT jirigalaenhe modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT weisong modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT zhaoli modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT tianhu modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT pingzhu modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT jianjunli modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT yuzhenwang modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT yijiezhang modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT xiaobingfu modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting
AT shahuang modelinghumanhypertrophicscarswith3dpreformedcellularaggregatesbioprinting